Chimeron Bio

Pre-clinical

Philadelphia, United StatesFounded 2015chimeron.com

Chimeron Bio is a private, pre-clinical stage biotech based in Philadelphia, developing a transformative platform for in-vivo genetic medicine. Its core innovation, the ChaESAR™/MultiPlex™ platform, utilizes self-amplifying RNA to deliver large, multi-gene payloads directly to patients, enabling weeks-long expression for complex therapies like CAR-T without ex vivo manufacturing. The company is advancing a pipeline in oncology and autoimmunity, has secured notable NIH grant funding and strategic manufacturing partnerships, and is led by a seasoned team with deep RNA and biotech experience, including a former Moderna CSO on its board.

Founded

2015

Focus

RNA & Gene TherapyViral Technology

AI Company Overview

Technology Platform

The ChaESAR™/MultiPlex™ platform utilizes self-amplifying RNA (saRNA) to enable the direct, in-vivo delivery of large (up to 20kb), complex multi-gene therapeutic payloads with weeks-long expression and a non-viral safety profile.

Funding History

Total raised: $14.8M

Series A$12MUndisclosedJul 15, 2022

Seed$2.8MUndisclosedNov 15, 2020

Opportunities

The primary opportunity is to disrupt the CAR-T therapy market by shifting from a complex, ex vivo manufacturing model to a simple, scalable in-vivo injection, dramatically improving patient access and cost.

The platform's versatility also creates opportunities in cancer vaccines, autoimmune disease, and genetic disorders, leveraging the same core delivery technology.

Risk Factors

Key risks include the high failure rate inherent in pre-clinical biotech, the significant scientific challenge of achieving safe and effective in-vivo genetic reprogramming, and intense competition from better-funded companies in the cell/gene therapy and RNA spaces.

Competitive Landscape

Chimeron competes with companies developing in-vivo cell engineering (e.g., Umoja Biopharma, Ensoma) and next-gen RNA delivery platforms. Its differentiation lies in the combination of large multi-gene payload capacity and weeks-long expression using its proprietary saRNA technology, aiming to overcome limitations of viral vectors and standard LNPs.